Ingevity Corporation’ €590m acquisition of Perstorp UK Limited

Eversheds Sutherland has advised Ingevity Corporation on its €590m acquisition of Warrington-based Perstorp UK Limited, the caprolactone division of the wider Perstorp Group.

The transaction, which is subject to regulatory approval and expected to close Spring 2019, is NYSE-listed Ingevity’s first major UK acquisition. It will increase the company’s range of products and geographic reach, while offering the potential for significant business growth.

The corporate team was led by Partners Nicola Brookes (UK, in picture) and Simon Masters (UK) alongside Associate Charlotte Singh (UK). Support was provided from the commercial, environmental, IP, employment and pensions, tax, real estate and banking teams including Partners Jonas Bratt (Sweden), Miriam Van Ee (Netherlands), and associates Douglas Dahlin (Sweden) and Laila Kouchi (Netherlands). Partner Meltem Kodaman (US) and Counsel Stephani Hildebrandt (US) provided advice on the US aspects of the transaction.

Eversheds Sutherland teams in Spain and Germany assisted competition Partner Kate Newman (UK) and Associate Todor Papanov (UK).

Involved fees earner: Jonas Bratt – Eversheds Sutherland; Nicola Brookes – Eversheds Sutherland; Douglas Dahlin – Eversheds Sutherland; Stephani Hildebrandt – Eversheds Sutherland; Meltem Kodaman – Eversheds Sutherland; Laila Kouchi – Eversheds Sutherland; Simon Masters – Eversheds Sutherland; Kate Newman – Eversheds Sutherland; Todor Papanov – Eversheds Sutherland; Charlotte Singh – Eversheds Sutherland; Miriam Van Ee – Eversheds Sutherland;

Law Firms: Eversheds Sutherland;

Clients: Ingevity Corporation;